Home›Metoprolol Succinate Er

Metoprolol Succinate Er

Also known as: Kapspargo

Route: Oral

Check Metoprolol Succinate Er Interactions →

11 interactions on record

Metoprolol Succinate Er has 11 known drug interactions based on U.S. FDA drug labeling data. 6 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Clonidine, Digitalis Glycosides, Diltiazem. Patients taking Metoprolol Succinate Er should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 11
Major: 6
Moderate: 5

Major (6)

Metoprolol Succinate Er + Clonidine— Concomitant use increases bradycardia risk. Withdraw beta-blocker several days before clonidine withdrawal to avoid rebo…
Metoprolol Succinate Er + Digitalis Glycosides— Concomitant use with metoprolol succinate ER slows AV conduction and decreases heart rate, increasing bradycardia risk.
Metoprolol Succinate Er + Diltiazem— Calcium channel blocker that slows AV conduction and decreases heart rate; concomitant use with metoprolol increases bra…
Metoprolol Succinate Er + Monoamine Oxidase Inhibitors (Maois)— Catecholamine depleting drugs with additive effect when given with metoprolol succinate ER, may cause hypotension or mar…
Metoprolol Succinate Er + Reserpine— Catecholamine depleting drug with additive effect when given with metoprolol succinate ER, may cause hypotension or mark…
Metoprolol Succinate Er + Verapamil— Calcium channel blocker that slows AV conduction and decreases heart rate; concomitant use with metoprolol increases bra…

Moderate (5)

Metoprolol Succinate Er + Fluoxetine— Strong CYP2D6 inhibitor that doubles metoprolol concentrations and decreases cardioselectivity; close monitoring require…
Metoprolol Succinate Er + Metoprolol— Observe patients treated with metoprolol succinate extended-release tablets plus a catecholamine depletor for evidence o…
Metoprolol Succinate Er + Paroxetine— Strong CYP2D6 inhibitor that doubles metoprolol concentrations and decreases cardioselectivity; close monitoring require…
Metoprolol Succinate Er + Propafenone— Strong CYP2D6 inhibitor that doubles metoprolol concentrations and decreases cardioselectivity; close monitoring require…
Metoprolol Succinate Er + Quinidine— Strong CYP2D6 inhibitor that doubles metoprolol concentrations and decreases cardioselectivity; close monitoring require…

Metoprolol Succinate Er + Clonidine⚠️Major

Concomitant use increases bradycardia risk. Withdraw beta-blocker several days before clonidine withdrawal to avoid rebound hypertension exacerbation.

Metoprolol Succinate Er + Digitalis Glycosides⚠️Major

Concomitant use with metoprolol succinate ER slows AV conduction and decreases heart rate, increasing bradycardia risk.

Metoprolol Succinate Er + Diltiazem⚠️Major

Calcium channel blocker that slows AV conduction and decreases heart rate; concomitant use with metoprolol increases bradycardia risk.

Metoprolol Succinate Er + Monoamine Oxidase Inhibitors (Maois)⚠️Major

Catecholamine depleting drugs with additive effect when given with metoprolol succinate ER, may cause hypotension or marked bradycardia with vertigo, syncope, or postural hypotension.

Metoprolol Succinate Er + Reserpine⚠️Major

Catecholamine depleting drug with additive effect when given with metoprolol succinate ER, may cause hypotension or marked bradycardia with vertigo, syncope, or postural hypotension.

Metoprolol Succinate Er + Verapamil⚠️Major

Calcium channel blocker that slows AV conduction and decreases heart rate; concomitant use with metoprolol increases bradycardia risk.

Metoprolol Succinate Er + Fluoxetine🟡Moderate

Strong CYP2D6 inhibitor that doubles metoprolol concentrations and decreases cardioselectivity; close monitoring required.

Metoprolol Succinate Er + Metoprolol🟡Moderate

Observe patients treated with metoprolol succinate extended-release tablets plus a catecholamine depletor for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. 7.2 CYP2D6 Inhibitors Drugs that are strong inhibitors of CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone were shown to double metoprolol concentrations. While there is no information about moderate or weak inhibitors, these too are likely to increase metoprolol concentration.

Metoprolol Succinate Er + Paroxetine🟡Moderate

Strong CYP2D6 inhibitor that doubles metoprolol concentrations and decreases cardioselectivity; close monitoring required.

Metoprolol Succinate Er + Propafenone🟡Moderate

Strong CYP2D6 inhibitor that doubles metoprolol concentrations and decreases cardioselectivity; close monitoring required.

Metoprolol Succinate Er + Quinidine🟡Moderate

Strong CYP2D6 inhibitor that doubles metoprolol concentrations and decreases cardioselectivity; close monitoring required.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.